View More Recent Stories
-
SciSparc (SPRC) Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
-
SciSparc (SPRC) Announces Receipt of Nasdaq Minimum Bid Price Notification
-
SciSparc (SPRC) Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
-
SciSparc (SPRC) Enters Non-binding LoI for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio
